Cytomegaloviral Infection clinical trials
24 active trials name this condition. Describe your situation to see which ones look like a fit.
Refine by biomarker
By location
- Study Evaluating the Efficacy and Safety of Artesunate
- Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
- Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
- A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
- A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
- A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
- R-MVST Cells for Treatment of Viral Infections
- Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
- Third Party Viral Specific T-cells (VSTs)
- Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
- R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
- TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
- Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
- Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
- CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients
- Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study
- Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients
- T Cell Therapy of Opportunistic Cytomegalovirus Infection
- The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients
- Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant
- Letermovir for R+ Study
- CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients
- Anti-viral T-cell Therapy by Gamma Capture
- A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Cytomegaloviral Infection” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.